$-1.74 EPS Expected for Agios Pharmaceuticals Inc (AGIO)

October 7, 2017 - By test

 $ 1.74 EPS Expected for Agios Pharmaceuticals Inc (AGIO)
Investors sentiment increased to 2.04 in 2017 Q2. Its up 0.71, from 1.33 in 2017Q1. It increased, as 14 investors sold Agios Pharmaceuticals Inc shares while 32 reduced holdings. 22 funds opened positions while 72 raised stakes. 44.72 million shares or 14.71% more from 38.98 million shares in 2017Q1 were reported.
Asset Mgmt One Limited reported 48,111 shares. Voya Inv Mgmt Ltd Co reported 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). California State Teachers Retirement Sys accumulated 74,157 shares. Bancshares Of America De reported 28,575 shares. Northern holds 232,802 shares. Redmile Gp Ltd Com holds 2.13% or 681,165 shares. Daiwa Sb Invests Ltd has 3,311 shares. 2.68 million were reported by Blackrock. Guggenheim Cap Ltd Llc owns 62,462 shares for 0.01% of their portfolio. First Trust Advsr Lp reported 973,870 shares. California Public Employees Retirement System, California-based fund reported 34,900 shares. Meeder Asset Mngmt has 63 shares. State Board Of Administration Of Florida Retirement System reported 50,629 shares. Valley Advisers Incorporated accumulated 0% or 157 shares. Two Sigma Securities Ltd, a New York-based fund reported 4,630 shares.

Since May 1, 2017, it had 0 buys, and 4 selling transactions for $497,855 activity. The insider Schenkein David P sold $150,180. Cantley Lewis Clayton Jr. sold $95,885 worth of stock or 2,036 shares.

Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on November, 2. They expect $-1.74 EPS, down 6.75 % or $0.11 from last year’s $-1.63 per share. After $-1.78 actual EPS reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -2.25 % EPS growth. The stock decreased 0.52% or $0.37 on October 6, reaching $70.45. About 284,949 shares traded. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since October 8, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 38 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Neutral” rating by TH Capital given on Monday, November 9. Leerink Swann downgraded the shares of AGIO in report on Monday, December 7 to “Market Perform” rating. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Neutral” rating given on Monday, June 26 by Janney Capital. The company was maintained on Tuesday, August 8 by Cowen & Co. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Buy” rating by Cowen & Co on Tuesday, June 6. The firm has “Overweight” rating by JP Morgan given on Monday, June 13. The firm earned “Neutral” rating on Wednesday, March 2 by Janney Capital. The company was maintained on Tuesday, August 1 by Cowen & Co. The firm has “Outperform” rating by Credit Suisse given on Thursday, January 21. The rating was maintained by Roth Capital on Monday, November 9 with “Neutral”.

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $3.39 billion. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. It currently has negative earnings. The Company’s cancer product candidates are enasidenib and ivosidenib , which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

More important recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Seekingalpha.com which released: “Agios, Amigos!” on May 26, 2017, also Seekingalpha.com published article titled: “Agios: Smooth First Mover In Cancer Metabolism”, Bostonglobe.com published: “Cambridge biotech Agios wins OK for its leukemia drug” on August 01, 2017. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) was released by: Nasdaq.com and their article: “Agios Pharmaceuticals Inc (AGIO) CEO David P Schenkein Sold $5.6 million of Shares” with publication date: October 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com